RTTNews BiotechDoubao · 实盘可交易 · 做多市场:美股▼ 亏 -6.85% · 已结算把握 4/10

北京时间·🕒 发布 19:45:02·⟳ 抓取 19:45:13 +11s·⚡ 决策 09-14 20:30:59 +45m46s·43.2 天前

Corbus 口服减重药 CRB-913 一期b期12周减重5%达统计显著，盘前一度涨超20%

方向明确的一期阳性读出+全新非incretin口服机制期权，小市值弹性大且事件前5日暴跌29%无抢跑；但仅Phase 1b、数据细节有限、二期在一年后、现金紧张摊薄风险高，盘前从+20%回落至+5%且区间剧烈（5.70–10.22）显示分歧，故只给probe并严格限制开盘追价。

📄 原文RTTNews Biotech↗ 原文

Corbus Announces Positive Phase 1b Weight-Loss Data Showing For Oral Candidate CRB-913; Stock Up

Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…

▼ 亏 -6.85%入场 09-14 盘前首笔 @8.652 → 离场 09-15 开盘 @8.080

日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(价格在入场线上方)、绿底 = 亏

💡 交易逻辑一期阳性验证外周CB1减重新机制，小市值未抢跑，限价小仓博二期期权

怎么买 限价买入　不高于 8.61、2 个交易日内有效

怎么卖止盈 +12%(半仓)/+22%(清仓) · 止损 -9% · 时间止损 3日

展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

分时走势

做多 CRBP.US Corbus Pharmaceuticals

5 日分时 · 15 分钟 · T-2 至 T+2

建仓日 09-14 分时 · 1 分钟

5 个交易日均已收盘,数据完整 · 美股含盘前盘后(灰底:美东 04:00 至收盘后 4 小时)

发布 09-14 19:45 北京(美东 09-14 07:45)
抓取 09-14 19:45 北京(美东 09-14 07:45)
入场 09-14 19:49 北京(美东 09-14 07:49) · 盘前首笔 @8.652
决策 09-14 20:30 北京(美东 09-14 08:30)
离场 09-15 21:30 北京(美东 09-15 09:30) · 开盘 @8.080

时间轴只含交易时段(午休、隔夜已压缩);横轴为北京时间,悬停看当地时间;蓝虚线 = 纸面入场价;建仓日图红线在昨收上方、绿线在下方

成交明细 · 纸面

做多 CRBP.US Corbus Pharmaceuticals

收益状态	-6.85% 已平仓
进场成交	2026-09-14 · 盘前首笔 · 09-14 19:49 北京 · @8.6518
离场成交	2026-09-15 · 开盘 · @8.08
毛收益	-6.61%
成本	+0.24%
净收益	-6.85%
计入收益	-6.85%
建仓日	2026-09-14 · 进场不早于新闻时刻 + 2 分钟

收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-28 01:29

研究档案

结论摘要

CRB-913 以全新外周 CB1 机制做出12周5%减重且无平台期、无精神安全性信号，消除了该机制最大的历史疑虑，对1.5亿美元小盘公司是实质去风险；但数据为早期顶线、幅度温和、融资压力大，盘前冲高回落，仅适合限价小仓试探。

🔎 新鲜度:最早出现 2026-09-14 · 扩散 low · price-in 风险 medium ↗

消息传播链

2026-09-14 07:00 ET首发Corbus 官网IR新闻稿一手源原文 ↗
公司官方首发CANYON-1阳性顶线：60mg组12周减重5%、统计显著、无平台期，二期计划2027H1
2026-09-14 07:45 ET财经媒体扩散RTTNews非一手原文 ↗
RTTNews报道时盘前报9.75美元、+20.07%，市场已在盘前开始重定价
2026-09-14 08:27 ET市场反应futu盘前行情非一手
盘前现价回落至8.55美元(+5.3%)，盘前区间5.70–10.22、成交约255万股，冲高回落显示多空分歧大
市场反应:盘前高10.22(+25.9%)后回落至8.55(+5.3%)

关键理由

外周限制性CB1反向激动剂首次在肥胖人群做出统计显著减重且避开CNS型CB1（利莫那班）的精神副作用，潜在first-in-class非incretin口服药的平台期权对1.57亿美元市值弹性显著
事件前一周股价-29%、市场未提前定价，7:00 ET官方首发新鲜；ObesityWeek 11月14日完整数据与2027H1二期启动构成后续催化链

主要风险

仅Phase 1b顶线：未披露样本量/p值/安慰剂校正，5%@12周减重幅度相对口服GLP-1并不突出，跨试验GI比较证据弱
Q1末现金仅约2570万美元，大涨后大概率启动增发摊薄；盘前区间5.70–10.22、自高点大幅回落且2天后有FOMC，开盘可能高开低走

反向证据

做多前查反向 · 来源 web · 日期 2026-08-06 · 影响 weakens
Q1末现金仅约2570万美元、持续烧钱，8月6日Q2更新后股价一周下跌29%（9/9单日-16.4%），市场已在交易融资/现金压力，涨后增发概率高
检索:Corbus Q2 2026 financial results cash runway stock offering dilution 原文 ↗
做多前查反向 · 来源 web · 日期 2026-09-14 · 影响 weakens
新闻稿未给样本量、p值与安慰剂校正细节；5%@12周绝对值不优于领先口服GLP-1，GI优势仅为跨试验比较，完整数据要等11月14日ObesityWeek
检索:CRB-913 5% weight loss 12 weeks versus oral GLP-1 orforglipron placebo adjusted criticism 原文 ↗

先例如何影响了这次决策

对本次决策的影响:先例不足直接导致仓位降为probe、限价≤前收+6%、3日时间止损，不重仓博开盘缺口

方向:无可用的干净对齐先例：检索到 Structure Therapeutics（9月8日口服amylin/GLP-1数据）、MBX Biosciences（5月一期减重数据）等类似机制/阶段事件，但未取得可锚定首发时刻的一手交易所/IR链接与完整事件窗口，未通过event_study锚点校验，不用于定幅度

涨幅量级:缺乏高相似aligned先例，tp/sl仅按小盘临床期biotech事件驱动波动与盘前价格结构保守设定，不引用不可靠涨幅中位数

形态:行业经验上小盘减重概念一期阳性常见盘前冲高、开盘后受增发预期与数据质疑压制而回吐，故收紧追价上限并降为probe

工具执行结果 · 成功 6 · 降级 0 · 失败 0 · 取消 0

search_processed_events 成功 stock_tools HTTP · 56 ms
{"result": "search_processed_events:agent query=`corbus crb-913 phase 1b canyon-1 obesity weight loss topline results | crbp crb-913 60mg 5% weight loss 12 weeks cb1 inverse agonist`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
fetch_decision_experience 成功 stock_tools HTTP · 44 ms
{
stock_quote 成功 stock_tools HTTP · 356 ms
{
web_search 成功 doubao_search · 2,595 ms
豆包搜索结果（原始查询:Corbus Pharmaceuticals CRBP cash balance market cap 2026 CRB-913 Phase 2 obesity；API SearchType:web）
web_search 成功 doubao_search · 2,482 ms
豆包搜索结果（原始查询:Corbus Q2 2026 financial results cash runway August 2026；API SearchType:web）
web_search 成功 doubao_search · 2,117 ms
豆包搜索结果（原始查询:small cap biotech positive Phase 1 obesity weight loss data stock reaction next day GLP-1 alternative；API SearchType:web）

原文全文

展开原文 · 9,098 字

Corbus Announces Positive Phase 1b Weight-Loss Data Showing For Oral Candidate CRB-913; Stock Up
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
Corbus Announces Positive Phase 1b Weight-Loss Data Showing For Oral Candidate CRB-913; Stock Up
By
TajSabreen Ahamed
✉
Published:
9/14/2026 7:45 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Corbus Pharmaceuticals Holdings, Inc. (
CRBP
), announced positive topline results from its CANYON-1 Phase 1b study evaluating daily oral CRB-913 for obesity, with the 60 mg dose achieving statistically significant and clinically meaningful mean weight loss of 5% at 12 weeks, with no plateau observed.
Obesity affects millions globally, and while GLP-1 receptor agonists have transformed treatment, many patients either cannot tolerate them or fail to achieve adequate therapeutic response. More than 60% discontinue treatment within the first year, underscoring the need for alternative mechanisms of action.
CRB-913, a peripherally restricted CB1 inverse agonist, was generally well tolerated, with psychiatric adverse events broadly in line with GLP-1 drugs and an emerging favorable GI tolerability profile based on cross-trial comparisons with published data from currently marketed oral GLP-1 therapies. Investigators noted that weight reduction had not yet plateaued by week 12 and that CRB-913 appeared to avoid depressive effects associated with earlier CNS-acting CB1 agents, supporting its potential as the first medicine in a new non-incretin obesity class.
Yuval Cohen, Ph.D., CEO of Corbus, stated that the results confirm the company's core hypothesis: a peripherally restricted CB1 inverse agonist can deliver safe, tolerable, and competitive oral alternative to GLP-1 therapies. He added that the company is preparing to advance CRB-913 into Phase 2 development following this milestone.
The data from the CANYON-1 Phase 1b trial have been selected for a late-breaking presentation at ObesityWeek 2026 on November 14, 2026, reflecting the significance of the findings within the obesity research community.
The company expects to initiate a Phase 2 monotherapy study in the first half of 2027. In addition, Corbus is evaluating the potential to combine CRB-913 with GLP-1 therapy.
CRBP has traded between $7.12 and $20.56 over the past year. The stock closed Friday's trading (September 11, 2026) at $8.12, down 1.46%. In pre-market trading the stock is at $9.75 up 20.07%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher Amid Inflation Data Release, Expectations Of Reopening Of Strait Of Hormuz
September 11, 2026 17:00 ET
Crude Oil Slumps Amid Rising Expectations Of An End To Hormuz Crisis, Profit-taking
September 11, 2026 14:41 ET
U.S. Dollar Advances Amid Oil-Linked Inflation Concerns, PPI Data Release
September 10, 2026 17:00 ET
U.S. Stocks Show Significant Rebound As Crude Oil Pulls Back Sharply
September 11, 2026 16:13 ET
Canadian Stocks Tumble Amid Increasing Concerns Of Oil-linked Inflation, Canada-U.S. Tariff War
September 10, 2026 16:32 ET
View More
Global Economics Weekly Update - Sep 07 – Sep 11, 2026
September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.
View More Videos
RELATED NEWS
Corbus Completes Final Patient Visit In Phase 1b CRB-913 Trial For Obesity
Corbus Says FDA Cleared Registrational TEMPO-1 Study Of CRB-701 For 2L-Oropharyngeal Cancer
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio As CMO
Latest Updates on COVID-19
COVID-19 Sees Late-Summer Rise Across 49 US States
September 03, 2026 12:52 ET
COVID-19 Infections Rising In All 50 US States, CDC Data Shows
August 20, 2026 14:09 ET
COVID-19 Pandemic Linked To Higher Loneliness And Isolation In England, Study Finds
August 19, 2026 14:02 ET
View More
Editor's Pick
Most Read
Most Emailed
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Google To Invest 13 Bln Euros In Finland To Develop AI Infra, Clean Energy
September 09, 2026 09:11 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Orion180 Plans Up To $340 Mln IPO
September 09, 2026 08:04 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
HP Partners With Red Hat For AI Workloads; Shares Up
September 09, 2026 15:46 ET
Apple Unveils New AirPods And Apple Watch Lineup With Enhanced Audio, Health And AI Features
September 09, 2026 16:47 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Blackstone To Buy Flow Control Holdings From Audax For Undisclosed Terms
September 10, 2026 11:20 ET
Atlantic HPC Group To Go Public Via Aperture AC Merger
September 11, 2026 08:16 ET
SEALSQ H1 Loss Widens From Higher Expenses; Reaffirms FY26 Outlook
September 11, 2026 13:24 ET
Ageas Completes Sale Of 30.95% Maybank Ageas Stake To Maybank For EUR 1.1 Bln
September 11, 2026 01:43 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
E79 Gold Mines Limited Full Year Sales Increase
September 09, 2026 01:00 ET
Holcim Invests In Cloud Cycle
September 09, 2026 03:16 ET
Everpure To Join S&P 500
September 09, 2026 01:09 ET
ASE Technology August Revenues Rise 34.6% Y-o-Y
September 09, 2026 03:18 ET
Scientex Berhad Q4 Income Climbs
September 09, 2026 01:12 ET
Victrex Plc Raises FY26 Underlying PBT View; Appoints Interim CFO; Stock Rises 12.8%
September 09, 2026 03:28 ET
Chime To Acquire Stride Bank
September 09, 2026 01:26 ET
Autohellas S.A. Reveals Fall In H1 Profit
September 09, 2026 03:33 ET
Antin Infrastructure Partners SAS Profit Drops In H1
September 09, 2026 01:29 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Vallourec, Aramco Ink Agreement For Supply Of Oil Country Tubular Goods
September 09, 2026 01:45 ET
TENPOS HOLDINGS Co Ltd. Reveals Retreat In Q1 Profit
September 09, 2026 05:03 ET
Editors Pick
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Loading...

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。